Health Catalyst, Inc. (NASDAQ:HCAT) Receives $9.27 Consensus PT from Analysts

Health Catalyst, Inc. (NASDAQ:HCAT) has been given a consensus recommendation of “Moderate Buy” by the eleven analysts that are presently covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $9.27.

HCAT has been the subject of several recent analyst reports. KeyCorp raised Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target for the company in a research note on Wednesday, January 8th. Wells Fargo & Company decreased their price target on Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a research note on Tuesday, January 21st. Piper Sandler dropped their price objective on Health Catalyst from $12.00 to $8.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 11th. Royal Bank of Canada cut their price objective on Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating for the company in a report on Thursday, February 27th. Finally, Stephens lowered their target price on Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating on the stock in a report on Thursday, March 6th.

Health Catalyst Trading Down 4.4 %

Shares of NASDAQ:HCAT opened at $4.33 on Friday. Health Catalyst has a fifty-two week low of $3.76 and a fifty-two week high of $9.24. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The company has a market cap of $304.01 million, a PE ratio of -3.21 and a beta of 1.41. The company’s 50-day moving average price is $4.98 and its 200 day moving average price is $6.80.

Insider Activity

In other Health Catalyst news, COO Daniel Lesueur sold 5,209 shares of the stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $5.76, for a total value of $30,003.84. Following the completion of the sale, the chief operating officer now owns 86,044 shares in the company, valued at $495,613.44. This represents a 5.71 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Linda Llewelyn sold 6,442 shares of the company’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $5.80, for a total transaction of $37,363.60. Following the completion of the transaction, the insider now directly owns 92,260 shares in the company, valued at $535,108. This trade represents a 6.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 56,530 shares of company stock worth $299,572 over the last 90 days. 2.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of HCAT. Fred Alger Management LLC acquired a new stake in shares of Health Catalyst in the 3rd quarter valued at $6,858,000. Point72 Asset Management L.P. raised its position in shares of Health Catalyst by 69.4% in the third quarter. Point72 Asset Management L.P. now owns 516,934 shares of the company’s stock valued at $4,208,000 after purchasing an additional 211,805 shares during the period. Impax Asset Management Group plc lifted its stake in shares of Health Catalyst by 7.7% in the fourth quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company’s stock worth $19,442,000 after buying an additional 195,525 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Health Catalyst by 4.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,443,036 shares of the company’s stock worth $11,749,000 after buying an additional 66,896 shares during the period. Finally, State Street Corp grew its stake in Health Catalyst by 2.5% in the 3rd quarter. State Street Corp now owns 1,163,754 shares of the company’s stock valued at $9,473,000 after buying an additional 28,251 shares during the last quarter. 85.00% of the stock is owned by institutional investors and hedge funds.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.